Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25984106 | 0.87 | LMNA (0.56) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25984092 | 0.83 | LMNA (0.56) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30405369 | 0.82 | NPC1 (0.56) | LMNANPC1RAB9ASMN1; SMN2RAF1 | |
| SCHEMBL23482203 | 0.82 | NPC1 (0.56) | LMNANPC1RAB9ASMN1; SMN2RAF1 | |
| SCHEMBL25984088 | 0.81 | LMNA (0.52) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30016396 | 0.81 | LMNA (0.51) | LMNANPC1RAB9ASMN1; SMN2RAF1 | |
| SCHEMBL28637538 | 0.81 | LMNA (0.51) | LMNANPC1RAB9ASMN1; SMN2RAF1 | |
| SCHEMBL25984465 | 0.79 | BRAF (0.49) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17542187 | 0.77 | LMNA (0.59) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30016951 | 0.77 | LMNA (0.60) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | LMNA 2596/4885NPC1 2922/4885RAB9A 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.